Bionano Genomics Inc Stock Price, News & Analysis

Bionano Genomics (BNGO) announced a study showcasing the effectiveness of optical genome mapping (OGM) for assessing the quality of hypoimmunogenic induced pluripotent stem cells (iPSCs). This research highlights OGM's ability to detect structural variants in CRISPR-edited cells that traditional methods missed, aiding in genomic integrity evaluation. The study also presents a method to reduce immune rejection risks with CRISPR-Cas9 genome editing. This advancement could enhance iPSC-mediated therapies and improve the safety and efficacy of regenerative medicine applications.

Bionano Genomics (BNGO) will participate virtually in the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. A pre-recorded presentation will be accessible on the Company’s Investor Resources page on September 12 at 7:00 am ET. Bionano Genomics focuses on genome analysis solutions, providing optical genome mapping technologies and diagnostic services, including testing for autism spectrum disorder and other neurodevelopmental disabilities. The Company aims to transform genomic research through advanced software and services.

Bionano Genomics (NASDAQ: BNGO) announced the publication of a pioneering study utilizing optical genome mapping (OGM) to investigate the effects of chromothripsis (cth) and TP53 abnormalities in chronic lymphocytic leukemia (CLL) patients with high genomic complexity. The research analyzed 162 CLL patients, confirming OGM's capability to detect cth and its correlation with chromosomal microarray results. While cth was linked to shorter time to first treatment, only TP53 mutations significantly influenced prognosis, indicating that TP53 abnormalities may be the main contributor to adverse outcomes. The study highlights OGM's unique detection power.

Bionano Genomics (Nasdaq: BNGO) has published a groundbreaking study demonstrating the effectiveness of optical genome mapping (OGM) for analyzing repeat expansion disorders. This research highlights OGM's superiority over the traditional Southern blot method, specifically in identifying repeat expansions in the RFC1 gene associated with conditions like CANVAS and adult-onset ataxia. The study screened 626 samples, confirming expanded RFC1 alleles using OGM, which could enhance diagnosis and research accuracy. The company plans to develop more tools for studying complex genetic disorders.

Bionano Genomics (BNGO) reported a record Q2 2022 revenue of $6.7 million, reflecting a 73% year-over-year growth. The company achieved all milestones outlined in its ELEVATE! program. The Saphyr system's installed base increased from 176 to 196, marking a 62% growth year-over-year. Despite the growth, gross margin decreased to 22% due to low yields on consumables. Operating expenses rose significantly, with a GAAP operating expense of $33.6 million. Bionano maintains a strong cash position of $187.3 million and keeps its full-year revenue guidance of $24 million to $27 million.

Bionano Genomics (BNGO) announced a groundbreaking study published in Leukemia, demonstrating the effectiveness of optical genome mapping (OGM) in prognosticating myelodysplastic syndrome (MDS). The study, conducted on 101 newly diagnosed patients, revealed that OGM altered prognostic risk scores for 17-21% of subjects and uncovered additional pathogenic variants in 13%. Compared to traditional methods, OGM detected nearly twice the number of pathogenic structural variants. The combination of OGM with next-generation sequencing (NGS) elevated the detection of significant clonal abnormalities in 97 out of 101 cases, suggesting OGM's potential as a crucial cytogenetic tool.

Bionano Genomics (BNGO) announced a conference call and webcast on August 4, 2022, at 4:30 p.m. ET to discuss its Q2 2022 financial results and corporate progress. Participants can register for the call to receive a dial-in number and pin. The event will be accessible via their website, and a replay will be available for 30 days. Bionano focuses on genome analysis solutions, including optical genome mapping and diagnostic services aimed at advancing research and clinical outcomes in genetics.

Bionano Genomics (BNGO) announced its participation in the Cancer Genomics Consortium (CGC) 2022 Annual Meeting, featuring 18 events including panel discussions and scientific presentations. Dr. Alka Chaubey will lead a session on Optical Genome Mapping (OGM) integration with Next Generation Sequencing (NGS) for cancer research. The conference will take place from July 31 to August 3, 2022, in St. Louis, Missouri, showcasing advancements in clinical genomics. Bionano's involvement underscores the growing importance of OGM in cancer research, with numerous presentations highlighting its applications.

Bionano Genomics, Inc. (Nasdaq: BNGO) announced a study highlighting the use of optical genome mapping (OGM) in analyzing changes in two induced pluripotent stem cell (iPSC) lines, WTC-11 and Tuba1-GFP, over 150 days. The research revealed significant genomic alterations, including hundreds of structural variants (SVs) undetected by traditional cytogenetic methods. This supports OGM's potential in regenerative medicine while raising concerns about the limitations of long-term iPSC culture. The findings accentuate OGM's value in pharmaceutical research and drug development.